
Scholar Rock is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. Our most advanced investigational product candidate, apitegromab (SRK-015), a
51 - 200 employees
Founded 2016
💰 $205M Post-IPO Equity on 2022-06
October 31
51 - 200
Director for National Accounts launching Scholar Rock’s SMA treatment apitegromab. Responsible for payer engagement, coverage, and patient access efforts.
🇺🇸 United States – Remote
💵 $230 - $265 / year
💰 $205M Post-IPO Equity on 2022-06
⏰ Full Time
🔴 Lead
👔 Director
October 29
51 - 200
EMEA Operations Coordinator to support operations and leadership at a biotech company in Zug. Join a pioneering team at a moment of growth and expansion across Europe.
🇨🇭 Switzerland – Remote
💰 $205M Post-IPO Equity on 2022-06
⏰ Full Time
🟡 Mid-level
🟠 Senior
⚙️ Operations
🗣️🇩🇪 German Required
October 20
51 - 200
Lead value and access strategy for market entry of apitegromab in EMEA. Focus on negotiation and sustainable access for rare disease therapies, primarily in Germany.
🗣️🇩🇪 German Required
October 20
51 - 200
Vice President of Medical Affairs leading medical affairs strategy across EMEA for Scholar Rock. Driving excellence and supporting evidence generation activities with key stakeholders in healthcare.
October 20
51 - 200
Head of Projects & Strategic Partnerships driving execution and cultivating partnerships for a biopharmaceutical company. Working closely with leadership on strategic projects and organizational alignment.
October 20
51 - 200
Vice President, General Manager leading expansion at Scholar Rock, advancing innovative therapies for serious diseases in Germany.
🗣️🇩🇪 German Required
September 25
51 - 200
Lead and build Scholar Rock's European Regulatory Affairs team to develop regulatory strategy and secure market access across Europe and Rest of World.